Jakarta, hitclubapk3 Indonesia
—
World Health Organization (
WHO
) released usage guidelines
medicine
Glucagon-Like Peptide 1 (GLP-1) for
obesity
.
Obesity has now become a chronic disease that is ‘endemic’ in various parts of the world.The figure has now reached more than 1 million billion obese people in the world.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
About 3.7 million deaths worldwide in 2024 will be attributed to obesity.This guideline was issued to address the problem of obesity which has become a global challenge.
Last September, WHO included GLP-1 drugs in the List of Essential Medicines for type-2 diabetes in high-risk groups.However, in the latest guidelines, WHO issued a conditional recommendation for the use of GLP-1 in obese patients.
“Obesity is a global health challenge, which WHO is committed to addressing. Our new guidelines recognize that obesity is a chronic disease that can be treated with comprehensive, lifelong care,” said WHO Director General Tedros Adhanom Ghebreyesus, according to the official website.
WHO
.
Ghebreyesus said that treatment alone would not solve the obesity crisis.However, he continued, GLP-1 drugs could help millions of people suppress the bad effects of obesity.
In the latest guidelines, GLP-1 drugs can be used by adults to treat long-term obesity.However, pregnant women are not included in it.
However, this recommendation is still conditional due to limited data on the long-term efficacy and safety of consuming GLP-1 drugs.
Apart from that, people undergoing therapy with GLP-1 are also required to combine it with a healthy diet and regular physical activity.
(asr)
[Gambas:hitclubapk3 Video]
